Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ºñ¾ËÄڿüº Áö¹æ°£ ȯÀÚ¿¡¼­ Áö¹æ°£¿°ÀÇ º´¸®ÇÐÀû ½ÉÈ­µµ¸¦ ¿¹ÃøÇÒ ¼ö ÀÖ´Â ÀÓ»óÀû ÁöÇ¥µé Clinical Predictors Reflecting the Pathologic Severity of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver

´ëÇѼÒÈ­±âÇÐȸÁö 2000³â 36±Ç 6È£ p.782 ~ 792
¼Ò¼Ó »ó¼¼Á¤º¸
±è»óÁø/Sang Jin Kim ¹ÚÁß¿ø/±è¹Ì°æ/±èÇüÁØ/È«¿äÇÑ/ÇѼºÇõ/±èÀç±Ô/À¯º´Ã¶/¹Ú½Ç¹«/Joong Won Park/Mi Gyung Kim/Hyung Joon Kim/Yo Han Hong/Sung Hyuk Han/Jae Gyu Kim/Byung Chul Yoo/Sil Moo Park

Abstract

¸ñÀû :ÀÓ»óÀûÀ¸·Î ÈçÇÑ ÁúȯÀÎ Áö¹æ°£ (fatty liver)
Àº ¾ËÄÚ¿Ã °ü·Ã ¿©ºÎ¿¡ µû¶ó ´ëº°µÇ´Âµ¥, ¾ËÄڿðú
¹«°üÇϸ鼭µµ ¸¸¼ºÀûÀÎ ºñ¾ËÄڿüº Áö¹æ°£Àº º´¸®
ÇÐÀûÀ¸·Î Áö¹æÁõ (steatosis)°ú Áö¹æ°£¿° (steatohepa-titis)
À¸·Î ºÐ·ùµÈ´Ù. ÃÖ±Ù ºñ¾ËÄڿüº Áö¹æ°£¿° (ÀÌÇÏ
NASH)Àº ´Ü¼øÇÑ Áö¹æÁõ°ú´Â ´Þ¸® ¾ËÄڿüº °£¿°°ú
À¯»çÇÏ°Ô ¼¶À¯È­°¡ ¹ß»ýÇÒ ¼ö ÀÖ°í ÀϺο¡¼­´Â °£
°æº¯ÁõÀ¸·Î ÁøÇàÇÒ ¼ö ÀÖÀ½ÀÌ ¾Ë·ÁÁö¸é¼­ NASH ¹ß
º´±âÀü°ú ÀÓ»ó»ó¿¡ ´ëÇØ ¸¹Àº °ü½ÉÀÌ ¸ð¾ÆÁ³´Ù. ÀÌ
¿¡ ¿¬±¸ÀÚµéÀº °£»ý°Ë»ó Áö¹æ°£À¸·Î È®ÀÎµÈ È¯ÀÚµé
À» ´ë»óÀ¸·Î ºñ¾ËÄڿüº Áö¹æÁõ°ú °¨º°µÉ ¼ö ÀÖ´Â
NASH ÀÇ ÀÓ»óÀû Ư¡À» È®ÀÎÇÏ°í NASH ÀÇ °£¼¶À¯
È­¸¦ Æ÷ÇÔÇÑ º´¸®Àû ½ÉÈ­µµ¸¦ ¿¹°ßÇÒ ¼ö ÀÖ´Â ºñħ
½ÀÀû ÀÎÀÚ¸¦ ãÀ½À¸·Î½á ºñ¾ËÄڿüº Áö¹æ°£ ȯÀÚÀÇ
Ä¡·á ¹æħ °áÁ¤¿¡ µµ¿òÀÌ µÇ°íÀÚ ÇÏ¿´´Ù. ´ë»ó ¹×
¹æ¹ý : 1993 ³âºÎÅÍ 1999 ³â±îÁö Áß¾Ó´ë ¿ë»êº´¿ø¼­
¸¸¼º °£ÁúȯÀ» ÀÌÀ¯·Î ½ÃÇàÇÑ °£»ý°Ë»ó Áö¹æ°£ÀÌ
°üÂûµÈ °æ¿ì´Â ÃÑ 72 ¿¹À̾ú´Ù. À̵é Áß HBsAg ¶Ç´Â
HBV DNA PCR ¾ç¼º, anti-HCV ¾ç¼º, ¾à¹°°ú µ¶¼º
°£ ¼Õ»ó º´·Â ¾ç¼º°ú »çȸÀû À½ÁÖ ÀÌ»óÀÇ À½ÁÖ·Â µî
ÀÌ ÀÖ´Â 27 ¿¹¸¦ Á¦¿ÜÇÑ ÈÄ ´ë»ó ȯÀÚµéÀÇ Á¤º¸¸¦ ¸ð
¸£´Â ÇÑ ¸íÀÇ º´¸®Àǻ簡 Á¶Á÷Ç¥º»À» ÀçÆǵ¶ÇÏ¿©
Áö¹æÁõ, ¼¶À¯È­, ¿°Áõ¼¼Æ÷ ħÀ± ¹× ±«»ç Á¤µµ¸¦ 3-5
´Ü°è·Î ±¸ºÐÇÏ¿´´Ù. À̵é Áß Áö¹æÁõ ¹üÀ§°¡ 10%¹Ì
¸¸ÀÎ 6 ¿¹¸¦ Ãß°¡·Î Á¦¿ÜÇÏ¿© ÃÖÁ¾ÀûÀ¸·Î 39 ¿¹¸¦ ´ë
»óÀ¸·Î ÇÏ¿´´Ù. ´ë»ó ȯÀÚµéÀÇ º´·Â°ú üÁú·®Áö¼ö
(body mass index,ÀÌÇÏ BMI),Ç÷ûÇÐÀû »ýÈ­Çа˻ç,
°£ÃÊÀ½ÆÄ°Ë»ç °á°ú µîÀ» ÈÄÇâÀûÀ¸·Î Á¶»çÇÏ¿´À¸¸ç
À̵é°ú º´¸®ÇÐÀû ½ÉÈ­µµ °£ÀÇ °ü°è¸¦ Åë°èÀûÀ¸·Î
»ìÆ캸¾Ò´Ù. °á°ú : 39 ¿¹ÀÇ ºñ¾ËÄڿüº Áö¹æ°£ ȯÀÚ
µé Áß ´Ü¼øÁö¹æÁõÀº 15 ¿¹, NASH ´Â 24 ¿¹À̾ú°í, Æò
±Õ ¿¬·ÉÀº °¢°¢ 32.7 ¼¼, 32.8 ¼¼, ³²³à ¼ººñ´Â 13:2,
17:7 ·Î¼­ ÀÇ¹Ì ÀÖ´Â Â÷ÀÌ°¡ ¾ø¾ú´Ù. BMI ¿Í Ç÷û °£
±â´É°Ë»ç, °øº¹½Ã Ç÷´ç, °£ÃÊÀ½ÆÄ°Ë»ç ½ÉÈ­µµ µî¿¡
¼­ µÎ ±º °£¿¡ ÀÇ¹Ì ÀÖ´Â Â÷À̸¦ º¸ÀÎ °ÍÀº BMI °¡
À¯ÀÏÇÏ¿´´Âµ¥ (Áö¹æÁõ 25.8 ¡¾2.8, NASH 28.4 ¡¾3.4,
p=0.025), BMI 28.9 ÀÌ»óÀ̸é NASH ÀÏ °¡´É¼ºÀÌ ¸Å
¿ì ³ô¾Ò´Ù. NASH ȯÀÚµé Áß 12.5%¸¸ÀÌ °£¼¶À¯È­°¡
¾ø¾ú°í, 29.2%°¡ Áߵ ÀÌ»óÀÇ ¼¶À¯È­¸¦ º¸¿´À¸³ª
°£°æº¯Áõ ¿¹´Â ¾ø¾ú´Ù. NASH ÀÇ º´¸®Àû ½ÉÈ­µµ¸¦
¹Ý¿µÇÏ´Â ÀÓ»óÁöÇ¥µé·Î´Â AST/ALT ºñ°¡ ³·À»¼ö·Ï
Áö¹æÁõ Á¤µµ°¡ ½ÉÇÏ¿´À¸¸ç (p=0.005),³ôÀº BMI (p=
0.001)¿Í ³·Àº ALT °ª (p=0.001)ÀÌ ½ÉÇÑ °£¼¶À¯È­¿Í
°ü°èµÇ¾ú´Ù. ÃÊÀ½ÆÄ°Ë»ç»ó Áö¹æº¯È­ Á¤µµ´Â º´¸®ÇÐ
Àû °Ë»ç»óÀÇ Áö¹æÁõ, ¼¶À¯È­, ¿°Áõ¼¼Æ÷ ħÀ±, ±«»ç
°¢°¢ÀÇ ½ÉÈ­µµ¸¦ ¹Ý¿µÇÏÁö´Â ¸øÇÏ¿´À¸³ª À̵é Àüü
ÀÇ ÇÕ°ú´Â ºñ·ÊÇÏ¿´´Ù (p=0.031).°á·Ð :ºñ¾ËÄڿüº
Áö¹æ°£ (fatty liver)ȯÀÚµé Áß¿¡¼­ üÁú·®Áö¼ö°¡ ³ô
À»¼ö·Ï Áö¹æÁõ (´Ü¼øÁö¹æ°£ )º¸´Ù´Â NASH ÀÏ °¡´É¼º
ÀÌ ³ôÀ¸¸ç, À̵é Áß ½ÉÇÑ ºñ¸¸°ú ³·Àº ALT °ªÀ» º¸
ÀÌ´Â °æ¿ì ½ÉÇÑ °£¼¶À¯È­ ¹ß»ý °¡´É¼ºÀÌ ³ôÀ¸¹Ç·Î
°£°æº¯Áõ ¹ß»ýÀ» ¸é¹ÐÈ÷ ÃßÀûÇÒ ÇÊ¿ä°¡ ÀÖ´Ù°í »ý
°¢µÈ´Ù.

Background/Aims: Nonalcoholic steatohepatitis (NASH) may progress to advanced liver disease. The aims of our study were to examine clinical factors distinguishing NASH from simple steatosis in patients with nonalcoholic fatty liver and to
identify
clinical predictors reflecting the pathologic severity in patients with NASH. Methods: For thirty-nine patients with fatty liver, medical history, body mass index (BMI), and the results of serological test and ultrasonography of liver, were
reviewed
retrospectively. Then, the clinical and biochemical data of nonalcoholic steatosis (NAS) and NASH was compared. Results: NAS was observed in fifteen patients (median age: 32.7, M:F=13:2) and NASH was observed in twenty-four patients (median age:
32.8,
M:F=17:7). Only body mass index (BMI) showed the significant difference between NASH (28.4¡¾3.4) and NAS (25.8¡¾2.8) (p<0.03). The incidence of NASH was high in patients with BMI over 28.9. Serum aspartate aminotransferase (AST)/alanine
aminotransferase
(ALT) ratio was reversely correlated with the degree of steatosis (p<0.01). Multivariate analysis showed the correlation between BMI and the degree of fibrosis (p<0.01) and the reverse-relation between serum ALT value and the degree of fibrosis
(p<0.01). Coclusions: BMI helps identify NASH in patients with nonalcoholic fatty liver. In patients with NASH, high BMI accompanied with low ALT value and severe fatty change on ultrasonography could suggest severe fibrosis. Thus, these patients
need a
close follow-up including a liver biopsy.

Å°¿öµå

ºñ¾ËÄڿüº Áö¹æ°£; NASH; ºñBºñC ¸¸¼º°£¿°; °£¼¶À¯È­; ¿¹ÃøÀÎÀÚ; Nonalcoholic fatty liver; NASH; Clinical predictors; NBNC cirrhosis;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

MEDLINE
KCI
KoreaMed
KAMS